替吉奥联合奥沙利铂或多西他赛治疗晚期胃癌的前瞻性随机对照研究  

Prospective randomized study of S-1 combined with oxaliplatin and docetaxel in the treatment of advanced gastric cancer

作　　者：潘险峰[1] 徐炎华[1] 龙健[1] 

机构地区：[1]华中科技大学同济医学院附属荆州医院肿瘤科,湖北荆州434020

出　　处：《疑难病杂志》2014年第10期1015-1018,共4页Chinese Journal of Difficult and Complicated Cases

摘　　要：目的探讨替吉奥合并奥沙利铂或多西他赛治疗晚期胃癌的近期疗效及安全性。方法 90例未经治疗的晚期胃癌患者,随机分为研究组(替吉奥联合奥沙利铂)和对照组(替吉奥联合多西他赛),每组45例。2组均口服替吉奥胶囊40 mg/m^2,2次/d,3周为1周期。其中研究组第1天联合奥沙利铂130 mg/m^2静脉滴注,3周为1周期;对照组第1天联合多西他赛60 mg/m^2静脉滴注,3周为1周期。2组均至少完成2个周期。比较治疗2周期后2组近期、远期疗效、不良反应和生活质量。结果研究组和对照组治疗6周有效率分别为55.6%和46.6%(x^2=0.71,P>0.05);疾病控制率分别为91.1%和84.4%(x^2=0.93,P>0.05)。研究组和对照组mTTP分别为6.1、4.7个月(t=1.842,P=0.069);mOS分别为11.4、12.3个月(t=0.896,P=0.387);PFS分别为8.3、7.6个月(t=1.273,P=0.206);OS分别为11.6、10.4个月(t=1.493,P=0.139)。研究组和对照组生存质量改善率分别为88.9%、80.0%(x^2=1.35,P=0.245)。研究组与对照组发生贫血分别为46.7%、26.7%(x^2=3.88,P=0.048);手足综合征分别为17.8%、40.0%(x^2=5.41,P=0.020);肝功能异常分别为11.1%、37.8%(x^2=8.66,P=0.003)。结论替吉奥联合奥沙利铂或者多西他赛,2种方案疗效相当,但替吉奥联合奥沙利铂的药物不良反应较少。Objective To explore the short-term efficacy and safety of docetaxel combined with oxaliplatin or S-1 in the treatment of advanced gastric cancer. Methods Ninty cases of untreated patients with advanced gastric cancer were randomly divided into study group （S-1 combined with oxaliplatin） and control group （S-1 combined with doeetaxel） ,45 cases in each group. The 2 groups were treated with S-I capsule 40 mg/m^2, bid, 3 weeks for one cycle. The study group＇ s first day＇ s treatment were combined with oxaliplatin 130 mg/m^2 intravenous drip, 3 weeks for one cycle; the control group＇ s first day＇ s treatment were plus with docetaxel 60 mg/m^2 intravenous drip, 3 weeks for 1 cycles. The 2 groups＇ treatment was completed at least 2 cycles. Compared 2 groups＇ recently, long-term efficacy, adverse reactions and quality of life after 2 cycle treatment. Results After 6 weeks treatment, the efficiency of study group and the control group＇ s were 55.6% and 46.6% （X^2 =0.71, P 〉0.05） ; disease control rate were 91.1% and 84.4% （X^2 =0.93, P 〉0.05）. The study group and the control group＇ s mTTP were 6.1 and 4.7 months （ t = 1. 842, P =0. 069） ; mOS were 11.4 and 12.3 months respectively （t = O. 896, P =0.387） ; PFS were 8.3 and 7.6 months respectively （ t = 1. 273, P =0.206） ; OS were 11.6 and 10.4 months （ t = 1. 493, P =0. 139）. The study group and the control group＇ s improvement of quality of life were 88.9% and 80.0% respectively （ X^2 = l. 35, P =0.245）. The study group and control group＇ s anemi^t were 46.7% and 26.7% （ X^2 = 3.88, P = O. 048 ） ; hand foot syndrome were 17.8 % and 40.0% respectively （ X^2 = 5.41, P = 0. 020 ） ; abnormal liver function were 11.1% and 37.8 % （ X^2 = 8.66, P = 0. 003 ）. Conclusion S-1 combined with oxaliplatin or docetaxel, a considerable effect of the two kinds of schemes, but S-1 combined with oxaliplatin has less adverse drug reaction.

关 键 词：替吉奥 多西他赛 奥沙利铂 晚期胃癌 

分 类 号：R735.2[医药卫生—肿瘤]